TD Cowen analyst Yaron Werber raised the firm’s price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- BeiGene receives European Commission approval for tislelizumab
- Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
- BeiGene price target lowered to $164.30 from $179.30 at BofA
- BeiGene price target lowered to $161 from $196 at Bernstein
- BeiGene Announces Executive Team Reshuffle and Director Pay Revision
